Role of CYP3A4 in kinase inhibitor metabolism and assessment of CYP3A4 activity
Tyrosine kinase inhibitors (TKIs) are small pharmacologically active molecules, which are administered orally at fixed doses to combat tumor cells. Although oral administration is advantageous, the variability of exposure is important for drug efficacy. Hence, the impact of individual CYP3A activity...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
December 2017
|
| In: |
Translational cancer research
Year: 2017, Jahrgang: 6, Heft: S10, Pages: S1592-S1599 |
| ISSN: | 2219-6803 |
| DOI: | 10.21037/tcr.2017.09.10 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.21037/tcr.2017.09.10 Verlag, kostenfrei, Volltext: http://tcr.amegroups.com/article/view/16370 
|
| Verfasserangaben: | Gerd Mikus, Kathrin Isabelle Foerster |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1582450625 | ||
| 003 | DE-627 | ||
| 005 | 20230427193225.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181031s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21037/tcr.2017.09.10 |2 doi | |
| 035 | |a (DE-627)1582450625 | ||
| 035 | |a (DE-576)512450625 | ||
| 035 | |a (DE-599)BSZ512450625 | ||
| 035 | |a (OCoLC)1341022050 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mikus, Gerd |e VerfasserIn |0 (DE-588)110903137 |0 (DE-627)691097941 |0 (DE-576)336988710 |4 aut | |
| 245 | 1 | 0 | |a Role of CYP3A4 in kinase inhibitor metabolism and assessment of CYP3A4 activity |c Gerd Mikus, Kathrin Isabelle Foerster |
| 264 | 1 | |c December 2017 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 31.10.2018 | ||
| 520 | |a Tyrosine kinase inhibitors (TKIs) are small pharmacologically active molecules, which are administered orally at fixed doses to combat tumor cells. Although oral administration is advantageous, the variability of exposure is important for drug efficacy. Hence, the impact of individual CYP3A activity as one of the most important enzymes regulating exposure is important to know. To assess the relevance of CYP3A’s contribution to the clearance of TKIs, 31 TKI European public assessment reports (EPAR) were evaluated. AUC ratios (AUCR) from drug-drug interactions studies with ketoconazole (strong CYP3A inhibitor) and rifampicin (strong CYP3A inducer) were calculated and a significant linear regression was found between both AUCRs (r 2 =0.6951) after nonlinear regression analysis of the log transformed data. In general, if CYP3A contributes to more than 50% to the overall clearance, dose adaptations should be applied. Phenotyping CYP3A by midazolam microdosing might be an applicable option in future to adjust the TKI dose to the individual CYP3A activity, which should then be validated by therapeutic drug monitoring (TDM) to achieve optimal—efficacious but non-toxic—drug concentrations. | ||
| 700 | 1 | |a Foerster, Kathrin |e VerfasserIn |0 (DE-588)118114602X |0 (DE-627)1662507089 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Translational cancer research |d Shatin : AME Publishing Company, 2012 |g 6(2017), S10, Seite S1592-S1599 |h Online-Ressource |w (DE-627)894990276 |w (DE-600)2901601-0 |w (DE-576)491668899 |x 2219-6803 |7 nnas |a Role of CYP3A4 in kinase inhibitor metabolism and assessment of CYP3A4 activity |
| 773 | 1 | 8 | |g volume:6 |g year:2017 |g number:S10 |g pages:S1592-S1599 |g extent:8 |a Role of CYP3A4 in kinase inhibitor metabolism and assessment of CYP3A4 activity |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21037/tcr.2017.09.10 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://tcr.amegroups.com/article/view/16370 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181031 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 118114602X |a Foerster, Kathrin |m 118114602X:Foerster, Kathrin |d 910000 |d 910100 |e 910000PF118114602X |e 910100PF118114602X |k 0/910000/ |k 1/910000/910100/ |p 2 |y j | ||
| 998 | |g 110903137 |a Mikus, Gerd |m 110903137:Mikus, Gerd |d 910000 |d 910100 |e 910000PM110903137 |e 910100PM110903137 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1582450625 |e 3030126803 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Gerd Mikus, Kathrin Isabelle Foerster"]},"id":{"eki":["1582450625"],"doi":["10.21037/tcr.2017.09.10"]},"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"December 2017"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"Shatin","dateIssuedDisp":"[2012]-","publisher":"AME Publishing Company"}],"id":{"zdb":["2901601-0"],"eki":["894990276"],"issn":["2219-6803"]},"disp":"Role of CYP3A4 in kinase inhibitor metabolism and assessment of CYP3A4 activityTranslational cancer research","type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"recId":"894990276","pubHistory":["Vol 1, no 1 (June 2012)-"],"titleAlt":[{"title":"Transl Cancer Res TCR"},{"title":"TCR"}],"part":{"text":"6(2017), S10, Seite S1592-S1599","volume":"6","extent":"8","year":"2017","pages":"S1592-S1599","issue":"S10"},"title":[{"title_sort":"Translational cancer research","subtitle":"TCR","title":"Translational cancer research"}]}],"physDesc":[{"extent":"8 S."}],"person":[{"display":"Mikus, Gerd","roleDisplay":"VerfasserIn","role":"aut","family":"Mikus","given":"Gerd"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Foerster, Kathrin","given":"Kathrin","family":"Foerster"}],"title":[{"title":"Role of CYP3A4 in kinase inhibitor metabolism and assessment of CYP3A4 activity","title_sort":"Role of CYP3A4 in kinase inhibitor metabolism and assessment of CYP3A4 activity"}],"recId":"1582450625","language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 31.10.2018"]} | ||
| SRT | |a MIKUSGERDFROLEOFCYP32017 | ||